Published in Vaccine Weekly, October 25th, 2006
According to recent research from the United States, "The deficiency of glucose-6-phosphatase (G6Pase) underlies life-threatening hypoglycemia and growth retardation in glycogen storage disease type Ia (GSD-Ia)."
"An adeno-associated virus (AAV) vector encoding G6Pase was pseudotyped as AAV8 and administered to 2-week-old GSD-Ia mice (n=9)," wrote D.D. Koeberl and colleagues at Duke University in Durham. "Median survival was prolonged to 7 months following vector administration, in contrast to untreated GSD-Ia mice that survived for only 2...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.